fda warning letters compounded semaglutide 2024 2025 Troubling Findings in Study of GLP-1 Compounders FDA warns consumers not to

Her story reflects how parents appreciate the convenience of a once-daily capsule while managing busy family life

In a previous study, we demonstrated that patients using the recommended weight loss dose of semaglutide for 60 weeks achieved weight loss of 8-11% of their initial body weight

Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial, lead investigator Hamlet Gasoyan said in a news release

Most users tolerate this range without gastrointestinal upset, though doses above 5 grams may cause loose stools